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FRANCE AND THE EARLY HISTORY OF ORGAN 
TRANSPLANTATION 
THOMAS E. STARZL* 
The different starting points and uneven emphasis of historical ac-
counts of transplantation [1] have tended to obscure the contributions 
to this field of some of the grand figures of French medicine and science. 
Clinical transplantation activity began in France within the first few 
years of the twentieth century when Jaboulay in Lyon [2] and others in 
France and Germany performed subhuman-primate-to-human kidney 
heterotransplantation [3-5]. In 1936, The Russian Yu Yu Voronoy of 
Kiev made the first known attempt at renal allotransplantation [6]. 
Transplantation lay largely dormant until 1951 when Rene Kuss [7] 
and Charles Dubost [8] of Paris and Marceau Servelle of Strasbourg [9] 
carried out a series of cadaveric renal transplantations. The kidneys 
were removed from convict donors after their execution by guillotine. 
The next year the French physician Jean Hamburger, working with the 
urologist Louis Michon at the Hospital Necker (Paris), reported the now 
commonplace transplantation of a kidney from a live volunteer donor 
[10]. The pelvic kidney transplant procedure originally used by Kuss 
and refined subsequently by the French surgeons has been used hun-
dreds of thousands of times since then including for the celebrated 
identical (monozygotic) twin transplantations performed by Murray 
(N obel Laureate 1990) and his associates [11] in Boston. 
Visitors flocked to France in the early 1950s to learn firsthand from 
this experience, including John Merrill of Boston, as Hume described in 
the classical account of his own clinical trials at the Peter Bent Brigham 
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Hospital [12]. The extensive discussion of the French experience by 
Hume was typical of this man whose awareness and acknowledgment 
of other people's work was noteworthy throughout his illustrious career. 
As important as these and later contributions of Kuss [13] and Ham-
burger [14] were, the scientific basis for transplantation in France went 
far deeper. The roots of histocompatibility research were nourished in 
France by Jean Dausset (Nobel Laureate 1980) [15]. In addition, George 
Mathe, the father of cell transplantation, was part of the Paris clique of 
the 1950s and early 1960s. 
The skills necessary to transplant the kidney (the only candidate organ 
until the 1960s) were applications of what were becoming conventional 
surgical practices after World War II. The vascular surgical technology 
came from the Frenchman Alexis Carrel [16] and had a pervasive effect 
on essentially all surgical specialties. Although Carrel understood that 
transplanted organs were not permanently accepted, the biologic speci-
ficity of the field of transplantation was defined by Medawar when he 
showed that rejection is an immunologic event [17, 18]. In retrospect, 
every further development was a logical and inevitable step from this 
beginning. If rejection was in fact an immune reaction, what could be 
more logical than to protect the organ transplant by weakening the 
immune system? Medawar's conclusion about the nature of rejection 
was strengthened when it was shown more than forty years ago that 
adrenal corticosteroids [19, 20] and total body irradiation [21], which 
already were known to diminish immunologic responses, significantly 
prolonged skin graft survival. 
The relatively modest delay of rejection of rodent skin grafts made 
possible with corticosteroids and total body irradiation was not an open 
invitation for clinical application. Nor was there a clinical mandate in 
the 1953 article by Billingham, Brent, and Medawar [22] that described 
permanent skin graft acceptance in a special circumstance not involving 
iatrogenic immunosuppression. The unique circumstance was the inoc-
ulation of fetal or perinatal mice with immunocompetent spleen cells. 
Instead of being rejected, these cells survived and endowed the recipient 
with the ability in later life to accept other allogeneic tissues (in their 
experiments, skin) from the original donor strain [22, 23]. 
As Billingham, Brent, and Medawar (later referred to as the "holy 
trinity") meticulously annotated, the impetus and rationale for these 
experiments came originally from the observation by Owen [24] that 
freemartin cattle (the calf equivalents of human fraternal twins) were 
permanent hematopoietic chimeras if placental fusion and fetal cross-
circulation had existed in utero. Burnet and Fenner [25] predicted that 
such chimerism and the ability to exchange other tissues could be in-
duced by the kind of experiment eventually performed with Medawar 
by Billingham and Brent whose definition of tolerance was that it "is 
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due to a primary central failure of the mechanism of the immunological 
reaction, and not to some intercession, at a peripheral level" [23]. 
The surgical interest generated by the demonstration that tolerance 
could be acquired was quickly dampened when it was learned by Bil-
lingham and Brent [26] with further experiments in mice that the pen-
alty for the prophylactic infusion of such donor cells could be lethal 
graft-versus-host disease (GVHD). Many of the inoculated mice failed 
to thrive ("runt disease") and had skin erosions, hair loss, diarrhea, 
diffuse pneumonitis, and characteristic changes in their lymphoid or-
gans. Donor immune cells were found everywhere in the recipient 
tissues. 
Producing specific and stable allogeneic (often called Medawarian) 
nonresponsiveness became the holy grail of transplantation when in 
1955, Main and Prehn [27] simulated in adult mice an environment 
which they likened to that in perinatal Billingham-Brent-Medawar ani-
mals. The three steps were (1) to cripple the immune system with su-
pralethal total body irradiation, (2) to rescue it with allogeneic bone 
marrow (creating a chimera), and (3) to engraft skin from the bone 
marrow donor. Their eHorts were successful. When the results of Main 
and Prehn were confirmed by Trentin [28], the prototype strategy for 
induction of tolerance in large animals and in humans appeared at first 
to be obvious. Bad news was close behind. Within a few months, it 
became clear that GVHD similar to that in the perinatal mouse model 
could be expected almost invariably after all bone marrow engraftments 
that "took" following irradiation, except those from perfectly histocom-
patible donors. 
Although the bubble had burst, Mannick, Lochte, Ashley, Thomas, 
and Ferrebee at Cooperstown, New York (an affiliate of Columbia Uni-
versity), produced bone marrow chimerism in 1958 in an irradiated 
beagle dog, followed by successful kidney allotransplantation from the 
original marrow donor [29]. The animal lived for seventy-three days 
before dying of pneumonitis and was the first "successful" example of 
a marrow-kidney chimera in a large animal. However, efforts by Hume 
et al. [30] and by others to extend the Main-Prehn irradiation plus bone 
marrow technology to mongrel dog kidney transplantation were totally 
unsuccessful. It was clear that this strategy could work in dogs (and 
humans) only when perfectly tissue matched marrow donors were used 
-usually littermates [31]. Under all other conditions, lethal GVHD, 
rejection, or both were to be expected. This appreciation' caused an 
early break in ranks between those interested in bone marrow trans-
plantation for the treatment of hematologic disorders and those to 
whom the bone marrow was only the means to the end of transplanta-
tion of a needed solid organ of which the kidney was the sole candidate 
at the time. 
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From this point onward, the therapeutic philosophies of bone marrow 
and solid organ transplantation took separate pathways-one depen-
dent and the other seemingly independent of classical tolerance induc-
tion. In spite of the consequent donor pool limitations (essentially only 
perfectly matched siblings being permissible), bone marrow transplanta-
tion-first accomplished clinically in 1968 by Robert Good of the Uni-
versity of Minnesota [32J and soon thereafter by Thomas (Nobel Laure-
ate 1990) [33] and van Bekkum [34]-matured into accepted clinical 
therapy for hematologic diseases and an assortment of other indications. 
In contrast, solid organ transplant surgeons were quick to abandon 
efforts to produce specific allogeneic unresponsiveness with bone mar-
row. In Boston, Murray and Merrill [35] used the Main-Prehn principle 
of recipient preparation in their first two attempts at human kidney 
allotransplantation in 1958, but eliminated the bone marrow component 
for the next ten recipients, using sublethal total body irradiation alone 
[35, 36]. Although eleven of their twelve irradiated recipients died after 
o to 28 days, the survivor, the recipient of a fraternal twin kidney in 
January 1959, lived until 1979 and was the first example of a successful 
transplantation beyond the identical twin [35-37]. 
Five months later, Hamburger et al. [14, 38,39] added a second suc-
cessful fraternal (dizygotic) twin case. This patient had good renal func-
tion until his death twenty-six years later from carcinoma of the urinary 
bladder. However, in the Boston and Paris fraternal twin recipients, the 
possibility remained that their individual placentas had cross-circulated 
with those of their kidney donors, like the conditions in Owen's freemar-
tin cattle. This possibility was precluded in the further extraordinary 
kidney transplant experience in France during 1960 and 1961 using 
total body irradiation without bone marrow reconstitution. Hamburger 
et a1. [14, 39] succeeded with kidney transplantation from a sibling and 
a first cousin. The cousin kidney functioned for eighteen years before 
retransp1antation was performed without interim dialysis in a patient 
who now is a member of the French parliament and the longest surviv-
ing kidney allograft recipient (thirty-two years) from that heroic and 
primitive era [40]. 
Also in Paris, Rene Kuss had long-term survival of three of six irradi-
ated patients treated with kidney transplantation from January 1960 
through 1961 [13,41]. This was a truly extraordinary achievement be-
cause two of Kuss's long-surviving patients were given nonrelated kid-
neys (the first in June 1960) that functioned for seventeen and eighteen 
months. During the critical period of 1959 through early 1962, the 
cumulative French experience was the principal (and perhaps the only) 
justification to continue clinical kidney transplantation trials [42]. By 
showing that bone marrow infusion was not a necessary condition for 
substantial prolongation of kidney grafts, the stage was set for the transi-
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tion to drug therapy. In fact, Kuss was using 6-mercaptopurine and 
steroids as adjuvant therapy in his patients as early as 1960 [\3]. 
Those examining this period historically have been inclined to con-
sider irradiation-induced and drug-induced graft acceptance as differ-
ent phenomena [4, 36, 37]. However, it seems certain that the Boston 
and Paris fraternal-twin kidney recipients, as well as the five long-
surviving nontwin French recipients, had achieved to variable degrees 
the kind of graft acceptance that later was seen in tens of thousands of 
drug-treated humans after all kinds of whole organ transplantation. 
The fact that the mechanism was the same has been appreciated only 
in the last few months when it was realized that extensive migration and 
repopulation of tissue leukocytes (most obviously of dendritic cells) from 
graft to host and vice versa are events common to the "acceptance" 
of all solid organs using any immunosuppressive modality-creating 
chimerism in the graft but also systemically in the recipient [43]. What 
has been achieved with drugs and antilymphoid agents compared to 
sublethal irradiation is a greater ease and reliability of achieving this 
transition. 
In view of the historic developments through 1960, it was not surpris-
ing that the search for immunosuppressive drugs was focused at first 
on myelotoxic agents that were viewed as "space makers" for new donor 
or recovering recipient bone marrow, and thus the pharmacologic 
equivalent of total body irradiation. Willard Goodwin of Los Angeles 
achieved sublethal bone marrow "burnout" with methotrexate and 
cyclosphamide in a living related kidney recipient in September 1960, 
who subsequently developed rejection that was reversed with predni-
sone. This was the first example of protracted human kidney graft sur-
vival (143 days) with drug treatment alone [44]. 
Kidney transplant surgeons were quick to appreciate that myelotox-
icity should be avoided, not deliberately imposed. The most important 
step in this evolution was the discovery by Schwartz and Dameschek 
that 6-mercaptopurine was immunosuppressive without bone marrow 
depression in non transplant models [45]. Within a few months, 
Schwartz and Dameschek [46] and Meeker (working with Good) [47] 
showed that this drug could mitigate skin graft rejection in rats. Close 
behind, Caine [48] and Zukoski [49] demonstrated independently of 
each other that kidney rejection in dogs also was ameliorated. 
What was achieved in the early kidney transplant experiments was 
delay of the inevitable rejection or else death of the animal from overim-
munosuppression. However, occasional examples of long-term or seem-
ingly permanent allograft acceptance were observed throughout 1962 
and 1963 [50-53]-defined as long survival of transplanted mongrel 
kidneys after a four- to twelve-month course of 6-mercaptopurine or 
azathioprine was stopped. Since then, each new major immunosuppres-
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sive agent (or drug cocktail regimen), including cyclosporine and FK 
506, has generated excited claims of the same phenomenon. Through-
out the years, the most potent agents for induction of this state have 
been the antilymphoid sera (ALS) and globulins (ALG) that at the begin-
ning were polyclonal agents [54, 55]-but later highly specific mono-
clonal preparations [56]. Although variable in its incidence, the graft 
acceptance seen with all these modalities was indistinguishable and thus 
was not a treatment-specific phenomenon. 
This new kind of graft acceptance in outbred dogs was easier to pro-
duce with drugs than with total body irradiation, but the number of 
absolute examples was (and is) extremely small in contrast to what can 
be achieved today in small rodents. In summarizing his research with 
CaIne, Alexandre, Sheil, and others using azathioprine [36], Murray 
described a twenty day mortality of approximately 50% and a three-
month mortality of 90% in a series of 120 mongrel dogs given daily 
treatment. Eventually a handful of surviving animals (perhaps <5%) 
was the distillation from a thousand experiments with 6-mercaptopurine 
or azathioprine performed in Boston by Murray's team in work that was 
initiated with the arrival there of Sir Roy CaIne in June 1960 [52]. 
The animals proudly displayed as chronic survivors in laboratories in 
Boston, Denver, Richmond, and Minneapolis were those precious few 
who had run the gauntlet of therapy to the point where treatment was 
stopped. Our results in Colorado were similar to those in Boston but 
with one striking difference. Adrenocortical steroids were shown to re-
verse rejection in 88% of our dogs, sometimes in spectacular fashion, 
before the steroids almost always caused fatal peptic erosions of the 
gastrointestinal tract [57]. 
It was on this dismal record that the clinical kidney transplant trials 
of the early 1960s were based. In a display of optimism that would not 
be tolerated in today's clinical research climate, the rare exception was 
given more weight than the customary failure. Thus, the poor results 
came as no surprise when the drugs were first used for patients in the 
same way as had been tried in the dogs [36, 58]. However, one of the 
Boston patients whose transplantation under azathioprine was in April 
1962 had functional graft survival for more than eighteen months after 
receiving the kidney of a patient who could not be weaned from cardio-
pulmonary bypass after open heart surgery. This allograft, which pro-
vided a BUN of 100 mg% at twelve months, failed between eighteen 
and twenty-four months, and the patient died at twenty-seven months 
[59]. The transplanted kidney had been obtained from a patient under-
going cardiac surgery whose heartbeat could not be restored, making 
the conditions unusually advantageous physiologically because cardio-
pulmonary bypass was in effect [60]. 
In Colorado, where the synergism of azathioprine and prednisone 
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was known from the animal work, these two drugs were used together 
from the outset with results that exceeded everyone's expectations [61, 
62] and precipitated a revolution in clinical transplantation. Success 
hinged on the fact that acute rejection usually could be reversed with 
prednisone, as had been shown in our dogs under baseline therapy with 
azathioprine [57], and as Goodwin had observed in a kidney recipient 
whose primary treatment had been with methotrexate and cyclophos-
phamide [44]. Both Hamburger [14] and Kuss [13] had administered 
steroids to their irradiated patients although no details were given. In 
a lapse of scholarship in our 1963 article [61 J, we failed to acknowledge 
the French use of steroids or the earlier experimental work of Bil-
lingham, Krohn, and Medawar [19J, and the American Morgan [20]. 
Although these oversights were corrected in our experimental report 
[57J, we already had unwittingly distorted all subsequent literature on 
this subject. 
The second fundamental observation in these patients was that the 
amount of drug treatment required to prevent rejection often became 
less in time [61], allowing the lifetime rehabilitation of some of the pa-
tients. Of the first sixty-four patients in the Colorado series compiled 
between 1962 and March 1964 [62], fifteen survived for the next twenty-
five years. Two stopped all immunosuppression without rejection for 
twenty-five and twenty-seven years, thus mimicking completely the phe-
nomenon occasionally seen in dogs and in the irradiated Boston and 
Paris fraternal twins. Nine other patients from the era preceding early 
1964, including three treated by David H ume of Richmond, were still 
alive in six other centers in the summer of 1989 [40J. It was noteworthy 
that none of these quarter-century survivors had been given a nonre-
lated kidney. The first such example in the world was a cadaver kidney 
recipient treated in Paris by Hamburger in October 1964 who passed 
the twenty-five-year mark in October 1989 [40]. 
The reversibility of rejection and change in host-graft relationship 
eventually were verified with all other transplanted organs, beginning 
with the liver [63]. Although immunosuppression has improved, the 
central therapeutic dogma for solid organ transplantation has changed 
very little in nearly thirty years. The dogma calls for daily treatment 
with one or two baseline drugs with further immune modulation by the 
highly dose-maneuverable adrenal cortical steroids to whatever level is 
required to maintain stable graft function (See table 1). This means 
that every solid organ recipient goes through a trial and potential error 
experience as drugs are weaned to maintenance levels. 
Nineteen fifty-nine through 1963 was truly an amazing period in the 
history of transplantation, leading to successes that exceeded the wildest 
expectations of the immunologists. At the outset, the Peter Bent Brig-
ham Hospital was the sole American forerunner of the new field, soon 
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TABLE 1 
IMMUNOSUPPRESSIVE TREATMENT FOR SOLID TRANSPLANTS 
Central Therapeutic Dogma 
I. Baseline therapy with one or two drugs 
2. Secondary adjustments with steroids or anti-
lymphoid agents 
3. Case-to-case trial (and potential error) of weaning 
Baseline Agents 
I. Azathioprine 
2. Cyclophosphamide 
3. Cyclosporine 
4. Cyclosporine-
azathioprine 
5. FK 506 
6. 506-azathioprine 
to be joined by Will Goodwin's UCLA program in 1960. By January 
1963, Goodwin's program had declared a temporary moratorium, but 
the active clinical centers in America had grown to three-the Brigham, 
Medical College of Virginia, and University of Colorado. There were 
scarcely more in all of Europe, but by this time the two in Paris already 
had been in existence for more than a dozen years. At the end of 1963, 
the gold rush was on with a wild proliferation of kidney transplant 
centers on both sides of the Atlantic. Trials with the liver, the next vital 
organ beyond the kidney, had started [64], and clinical heterotransplan-
tation with chimpanzee [65] and baboon [66] donors had been systemati-
cally tried with encouraging although ultimately unsatisfactory results. 
These events and subsequent ones could not have transpired in the 
way they did without the French pioneers, Hamburger the physician 
and Kuss the surgeon, and their friends in Boston whose vision was 
greater than that given to normal men and women. Workers in the two 
cities founded a clinical discipline where none existed before and then 
persisted despite allegations of folly or worse. The French successes 
with kidney transplantation over a three-year period from 1959 through 
early 1962 kept the flames alive when everyone else was failing. 
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THE HAMSTER AND THE RAT 
The hamster and the rat proclaim: 
"All your treadmills have been set 
-irrevocably-
in genetic and in social time." 
As if these voiceless thoughts, 
imprisoned in the attic of my mind, 
were some unbiological crime, 
unconnected and irrelevant 
to any atom's energetic fission. 
Beyond the radioactive isotopes 
on which our neighbors hang their hopes 
the urgent question stays: 
Will there be children still 
beyond the nuclear winter 
that turns our years to days? 
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